Retatrutide in Malaysia: The Next-Generation Weight-Loss Drug Explained

Retatrutide is the weight-loss drug everyone in the GLP-1 world is talking about — early trials show some of the largest results ever recorded. But there's an important catch most headlines leave out: it isn't approved or available yet, in Malaysia or anywhere else. Here's an honest, doctor-reviewed look at what retatrutide is, what the science actually shows, and what your real options are today.

What is retatrutide?

Retatrutide (development code LY3437943) is an experimental injectable medication being developed by Eli Lilly for chronic weight management and type 2 diabetes. It belongs to the same broad family as Ozempic and Mounjaro, but works on more targets at once.

Most GLP-1 drugs act on one or two hormone receptors. Semaglutide (Ozempic, Wegovy) is a single agonist — it mimics one hormone, GLP-1. Tirzepatide (Mounjaro, Zepbound) is a dual agonist — GLP-1 plus GIP. Retatrutide goes further: it is a triple agonist, acting on GLP-1, GIP and glucagon receptors together.

The theory is that hitting glucagon as well may increase energy expenditure on top of reducing appetite — potentially producing greater weight loss. That theory is still being tested in large trials.

What do the clinical trials show?

In a Phase 2 trial published in the New England Journal of Medicine (2023), participants on the highest dose (12 mg weekly) lost on average around 24% of their body weight after 48 weeks. For context, that is higher than the averages reported for semaglutide or tirzepatide in their own trials.

These are published research findings from controlled clinical trials, not a guarantee of individual results — and not a claim made by Seimbang. Larger, longer Phase 3 trials (Eli Lilly's TRIUMPH programme) are still ongoing, and final efficacy and safety data are not yet complete.

Is retatrutide available in Malaysia?

No. As of 2026, retatrutide is still an investigational drug. It has not been approved by the US FDA, the European EMA, or any major regulator, and it is not registered with Malaysia's NPRA. That means no licensed doctor or pharmacy in Malaysia can legally prescribe or dispense it.

Be very cautious of any website, clinic or seller claiming to offer “retatrutide” today. Because it isn't approved anywhere, anything sold under that name through unofficial channels is unregulated — you cannot verify what it actually contains, how it was made, or whether it is safe. This is a real risk, not a hypothetical one.

When might it be available?

Retatrutide's Phase 3 trials are expected to read out over the next couple of years. Even in the best case, regulatory approval in major markets like the US would likely come no earlier than 2026–2027, and availability in Malaysia would come later still — only after NPRA registration. Timelines for investigational drugs frequently shift, so any specific date today is guesswork.

What about side effects?

In trials, retatrutide's most common side effects were gastrointestinal — nausea, diarrhoea, vomiting and constipation — similar to other drugs in the GLP-1 class, and generally more likely at higher doses. Because the medication is still being studied, its full long-term safety profile is not yet established. This is one of the reasons the trial process exists.

What are your options right now?

The good news: you don't have to wait for a future drug to start. There are GLP-1 medications available and NPRA-recognised in Malaysia today — including semaglutide and tirzepatide — that have strong published evidence and years of real-world use.

At Seimbang, a licensed Malaysian doctor reviews your health profile and, if appropriate, prescribes a treatment that's available now, with ongoing support and medication delivered to your door. If and when newer options like retatrutide are approved and registered here, a doctor-led service is exactly where you'd want to access them safely.

Frequently Asked Questions